Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity

European Journal of Clinical Investigation

Volumn 27, Issue 10, 1997, Pages 802-811

  Bredie, S J H ^a   Demacker, P N M ^a   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHYLOMICRON; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0030730766     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1850734.x     Document Type: Review

References (148)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
4. Jukema JW, Bruschke AV, van Boven Aj et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
5. Effect of simvastatin on coronary atheroma: the Multicentre AntiAtheroma Study (MAAS) [published erratum appears in Lancet 1994 Sep, 10:344[8924]: 762]. Lancet 1994;:344:633-8.
6. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.
7. Assmann G, Schulte H, von-Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.
8. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med 1994;154:2714-20.
9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;39:213-19.
10. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68.
11. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1973;1:954-9.
12. Genest JJ, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
13. Rose HG, Kranz P, Weinstock M, Juliano J, Haft JI. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am J Med 1973;54:148-60.
14. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-7.
15. Brown HB, Lewis LA, Page IH. Mixed hyperlipemia, a sixth type of hyperlipoproteinemia. Atherosclerosis 1973;17:181-96.
16. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991;17:170-8.
17. Bredie SJH, van Drongelen J, Kiemeney LA, Demacker PNM, Beaty TH, Stalenhoef AFH. Segregation analysis of plasma apolipoprotein-B levels in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:834-40.
18. Austin MA, Horowitz H, Wijsman E, Krauss RM, Brunzell J. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis 1992;92:67-77.
19. Bredie SJH, de Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH. Comparison of gemfibrozil vs. simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995;75:348-53.
20. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147-56.
21. Stalenhoef AFH, Demacker PNM, Lutterman JA, van 't Laar A. Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia. Arteriosclerosis 1986;6:387-94.
22. Kwiterovich POJ, White S, Forte T, Bachorik PS, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholestcrolemia. Arteriosclerosis 1987;7:211-25.
23. Kwiterovich P, Beaty T, Bachorik P, Chen J, Franklin F, Georgopoulos L, Sniderman A. Pediatric hyperlipoproteinemia: the phenotypic expression of hyperapobetalipoproteinemia in young prohands and their parents. Prog Clin Biol Res 1988;255:89-105.
24. Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich PJ. Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol 1985;55:291-5.
25. Cullen P, Farren B, Scott J, Farrall M. Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. Arterioscler Thromb 1994;14:1233-49.
26. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich POJ. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci USA 1980;77:604-8.
27. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
28. Williams RR, Hunt SC, Hopkins PN et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988;259:3579-86.
29. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, Lalouel JM, Williams RR. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis 1989;9:335-44.
30. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
31. Kissebah AH, Alfarsi S, Evans DJ. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 1984;4:614-24.
32. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Inv 1980;10:17-22.
33. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992;12:1176-83.
34. Reymer PWA, Groenemeyer BE, Gagne E, Miao L, Appelman EEG, Seidel JC, Kromhout D et al. A frequently occuring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet 1995;4:1543-9.
35. Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA. Purification and characterization of acylation stimulating protein. J Biol Chem 1989;264:426-30.
36. Sniderman AD, Cianflone KM. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 1993;13:629-36.
37. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162-4.
38. Cabezas MC, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:804-14.
39. Benoist F, Grand-Perret T. ApoB-100 secretion by hepG2 cells is regulated by the rate of triglycéride biosynthesis but not by intracellular lipid pools. Arterioscler Thromb Vasc Biol 1996;16:1229-35.
40. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Metabolic control and disease, Bondy PK, Rosenberg LE, eds. Philadelphia: Saunders. 1980: 393-494.
41. Tornqvist H, Krabisch L, Belfrage P. Rapid assay for hormonesensitive lipase activity of adipose tissue. J Lipid Res 1972;13:424-6.
42. Fredrikson G, Stralfors P, Nilsson NO, Belfrage P. Hormone-sensitive lipase of rat adipose tissue. Purification and some properties. J Biol Chem 1981;256:6311-20.
43. Stralfors P, Bjorgell P, Belfrage P. Hormonal regulation of hormone-sensitive lipase in intact adipoeytes: identification of phosphorylated sites and effects on the phosphorylatian by lipolytic hormones and insulin. Proc Natl Acad Sci USA 1984;81:3317-21.
44. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;92:160-8.
45. Bredie SJH, Tack CJJ, Smits P, Stalenhoef AFH. Non-obese patients with familial combined hyperlipidemia are insulin resistant as compared with their non-affected relatives. Arterioscler Thromb Vasc Biol 1997;17:1465-71.
46. Wetterau JR, Zilversmit DB. Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes. Chem Phys Lipids 1985;38:205-22.
47. Wetterau JR, Zilversmit DB. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J Biol Chem 1984;259:10863-6.
48. Wetterau JR, Aggerbeck LP, Bouma ME et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001.
49. Stalenhoef AFH, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest 1986;78:722-8.
50. Stalenhoef AFH, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci USA 1984;81:1839-43.
51. Hoffer MJ, Bredie SJH, Boomsma DI et al. The lipoprotein lipase (Asn291-Ser) mutation is associated with elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 1996;119:159-67.
52. Ho Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-3.
53. Wojciechowski AP, Farrall M, Cullen P et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991;349:161-4.
54. Dallinga-Thie GM, XiangDong Bu, Van Linde-Sibenius-Trip M, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996;37:136-47.
55. Bredie SJH, Vogelaar JM, Demacker PNM, Stalenhoef AFH. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 1996;126:313-24.
56. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984;25:1570-6.
57. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 1984;4:225-31.
58. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-105.
59. Crouse JR, Parks JS, Schey HM, Kahl FR. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985;26:566-74.
60. Chapman MJ, Laplaud PM, Luc G, Forgez P, Brucken E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988;29:442-58.
61. Fisher WR. Heterogeneity of plasma low density lipoproteins manifestations of the physiologic phenomenon in man. Metabolism 1983;32:283-91.
62. Swinkels DW, Hak-Lemmers HL, Demacker PNM. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res 1987;28:1233-9.
63. Hokanson JE, Krauss RM, Albers JJ, Austin MA, Brunzell JD. LDL physical and chemical properties in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:452-9.
64. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295-308.
65. Lind BM, Littbarski R, Hohlbach G, Moller KO. Long-term investigations of serum cholesterol, serum triglyceride, and HDL cholesterol in heritable hyperlipidemic rabbits. Z Versuchstierkd 1990;33:245-9.
66. Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990;10:520-30.
67. Bredie SJH, Kiemeney LA, De Haan AFJ, Demacker PNM, Stalenhoef AFH. Inherited susceptibility determines the distribution of dense low density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet 1996;58:812-22.
68. Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 1994;272:305-8.
69. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
70. Campos H, Genest JJ, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-95.
71. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298-306.
72. Gardner CD, Fortman SP, Krauss RM. Association of small low-density lipoprotein particles with teh incidence of coronary artery disease in men and women. JAMA 1996;276(110): 875-81.
73. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276(11):882-8.
74. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G, Lupien PJ, Despres JP. Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95(1): 69-75.
75. Hammond MG, Fisher WR. The characterization of a discrete series of low density lipoproteins in the disease, hyper-pre-beta-lipoproteinemia. Implications relating to the structure of plasma lipoproteins. J Biol Chem 1971;246:5454-65.
76. Hammond MG, Mengel MC, Warmke GL, Fisher WR. Macromolecular dispersion of human plasma low-density lipoproteins in hyperlipoproteinemia. Metabolism 1977;26:1231-42.
77. Austin MA, Jarvik GP, Hokanson JE, Edwards K. Complex segregation analysis of LDL peak particle diameter. Genet Epidemiol 1993;10:599-604.
78. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67.
79. Fisher WR. The structure of the lower-density lipoproteins of human plasma: newer concepts derived from studies with the analytical ultracentrifuge. Ann Clin Lab Sci 1972;2:198-208.
80. de Graaf J, Swinkels DW, De Haan AFJ, Demacker PNM, Stalenhoef AFH. Both inherited susceptibility and environmental exposure determine the low density lipoprotein subfraction pattern distribution in healthy Dutch families. Am J Hum Genet 1992;51:1295-310.
81. Dormans TP, Swinkels DW, de Graaf J, Hendriks JCM, Stalenhoef AFH, Demacker PNM. Single-spin density-gradient ultracentrifugation vs. gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin Chem 1991;37:853-8.
82. Demacker PNM, Otvos JD, Schmitz G et al. Alternative approaches to lipoprotein analysis. In: Laboratory measurement of lipids, lipoproteins and apolipoproteins, Rifar N, Warnick GR, eds. Washington: AACC Press, 1994: 323-347.
83. Marzetta CA, Foster DM, Brunzell JD. Conversion of plasma VLDL and IDL precursors into various LDL subpopulations using density gradient ultracentrifugation. J Lipid Res 1990;31:975-84.
84. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986;77:663-72.
85. Fisher WR, Zech LA, Bardalaye P, Warmke G, Berman M. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL. J Lipid Res 1980;21:760-74.
86. Ginsberg HN, Ngai C, Wang XJ, Ramakrishnan R. Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations. Arterioscler Thromb 1993;13:842-51.
87. Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T. Reversible modification of human plasma low-density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem 1982;257:6509-17.
88. Granot E, Deckelbaum RJ, Eisenberg S, Oschry Y, Bengtsson-Olivecrona G. Core modification of human low-density lipoprotein by artificial triacylglycerol emulsion. Biochim Biophys Acta 1985;833:308-15.
89. Gambert P, Bouzerand-Gambert C, Athias A, Farnier M, Lallemant C. Human low density lipoprotein subfractions separated by gradient gel electrophoresis: composition, distribution, and alterations induced by cholesteryl ester transfer protein. J Lipid Res 1990;31:1199-210.
90. Levy E, Deckelbaum RJ, Thibault RL, Seidman E, Olivecrona T, Roy CC. In vitro remodelling of plasma lipoproteins in whole plasma by lipoprotein lipase in primary and secondary hypertriglyceridaemia. Eur J Clin Invest 1990;20:422-31.
91. Griffin BA, Packard CJ. Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 1994;5:200-6.
92. Watson TD, Caslake MJ, Freeman DJ et al. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb 1994;14:902-10.
93. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147-53.
94. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-49.
95. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 1984;74:2178-92.
96. Krauss RM, Hellerstein MK, Neese RA, Blanche PJ, LaBelle MA, Shames DM. Altered metabolism of large very low density lipoproteins in subjects with a predominance of small low dense lipoproteins (abstract). Circulation 1995;92(8):1-102(0480).
97. Austin MA. Genetics of low-density lipoprotein subclasses. Curr Opin Lipidol 1993;4:125-32.
98. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988;43:838-46.
99. Fisher WR, Hammond MG, Mengel MC, Warmke GL. A genetic determinant of the phenotypic variance of the molecular weight of low density lipoprotein. Proc Natl Acad Sci USA 1975;72:2347-51.
100. Austin MA, Newman B, Selby JV, Edwards K, Mayer EJ, Krauss RM. Genetics of LDL subclass phenotypes in women twins. Concordance, heritability, and commingling analysis. Arterioscler Thromb 1993; 13:687-95.
101. Nishina PM, Johnson JP, Naggert JK, Krauss RM. Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992;89:708-12.
102. Haffner SM, Stern MP, Miettinen H, Robbins D, Howard BV. Apolipoprotein E polymorphism and LDL size in a biethnic population. Arterioscler Thromb Vasc Biol 1996;16(9):1184-1188.
103. Vohl M-C, Tchernof A, Dionne FT et al. The apoB-100 gene EcoRI polymorphism influences the relationship between features of the insulin resistance syndrome and the hyper-apoB and dense LDL phenotype in men. Diabetes 1996;45:1405-11.
104. Austin MA, Wijsman E, Guo SW, Krauss RM, Brunzell JD, Deeb S. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genet Epidemiol 1991;8:287-97.
105. Rotter JI, Bu X, Cantor RM et al. Multilocus genetic determinants of LDL particle size in coronary artery disease families. Am J Hum Genet 1996;58:585-94.
106. Swinkels DW, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells. Biochim Biophys Acta 1990; 1047:212-22
107. de Graaf J, Hendriks JCM, Swinkels DW, Demacker PNM, Stalenhoef AFH. Differences in LDL receptor-mediated metabolism of three low density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis. Artery 1993;20:201-30.
108. Nigon F, Lesnik P, Rouis M. Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741-53.
109. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 1993;13:815-25.
110. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99.
111. Swinkels DW, Demacker PNM, Hendriks JCM, van 't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 1989;9:604-13.
112. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
113. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
114. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977;46:897-930.
115. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
116. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
117. Henriksen T, Mahoney EM, Steinberg D, Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981;78:6499-503.
118. Steinbrecher UP, Zhang HF, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radie Biol Med 1990;9:155-68.
119. Steinberg D. The oxidative modification hypothesis of atherogenesis: strengths and weaknesses. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X, International congress series 1066, New York: Elsevier, 1995:25-9.
120. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem 1989;264: 2599-604.
121. Endemann G, Stanton LW, Madden KS, Bryant CM. While RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993;268:11811-16.
122. de Rijke YB, van Berkel TJ. Rat liver Kupffer and endothelial cells express different binding proteins for modified low density lipoproteins. Kupffer cells express a 95-kDa membrane protein as a specific binding site for oxidized low density lipoproteins. J Biol Chem 1994;269:824-7.
123. Ottnad E, Parthasarathy S, Sambrano GR et al. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells. Proc Natl Acad Sci USA 1995;92:1391-5.
124. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
125. Tribble DL, van den Berg JJ, Motchnik PA et al. Oxidative susceptibility of low density lipoprotein subtractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA 1994;91:1183-7.
126. de Rijke YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH. The redox status of coenzym Q10 in total LDL as an indicator of in vivo oxidative modification: studies in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:127-33.
127. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
128. Franceschini G, Cassinotti M, Vecchio G et al, Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14:1569-75.
129. de Graaf J, Demacker PNM, Stalenhoef AFH. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med 1993;43:254-61.
130. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987;83:9-20.
131. de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 1993;13:712-19.
132. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:427-34.
133. Cortner JA, Coates PM, Liacouras CA, Jarvik GP. Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. J Pediatr 1993;123:177-84.
134. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300-10.
135. Rose HG, Haft GK, Juliano J. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin. Atherosclerosis 1976;23:413-27.
136. Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA 1987;84:5434-8.
137. Esterbauer H, Striegl G, Puhl H, Oberreither S, Rotheneder M, el-Saadani M, Jurgens G. The role of vitamin E and carotenoids in preventing oxidation of low density lipoproteins. Ann NY Acad Sci 1989;570:254-67.
138. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb 1993;13:590-600.
139. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-4.
140. Kleinveld HA, Naber AHJ, Stalenhoef AFH, Demacker PNM. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. Free Radic Biol Med 1993;15:273-80.
141. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women [see comments]. N Engl J Med 1993;328:1444-9.
142. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
143. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
144. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
145. Kushi LH, Folksom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334: 1156-62.
146. Randomized trial of vitamin E in patients with coronary diesease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-86.
147. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
148. Bakker-Arkema RC, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin. in patients with hypertriglyceridemia. JAMA 1996;275:128-133.